AstraZeneca has licensed Algen Biotechnologies’ AI-driven gene-editing platform, AlgenBrain, for up to $555 million to develop therapies for immune-related disorders, gaining exclusive rights to any approved treatments. The partnership aims to leverage AstraZeneca’s expertise and Algen’s innovative platform, which maps genes to disease outcomes, to accelerate therapy development.
Want More Context? 🔎
Loading PerspectiveSplit analysis...
